IBD — Inspire Corporate Bond ETF

Is IBD overbought or oversold? Here is the current MarketMoodz read.

Neutral As of October 3, 2026

Inspire Corporate Bond ETF (IBD) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The stock last closed at $23.02. The rating moved from Oversold to Neutral on September 29, 2026.

AI analysis

With limited issuer-specific data and light volumes during recent safe-haven flows, expect modest price rangebound behavior unless a clear macro catalyst shifts credit conditions materially.

Key factors

  • Macro risk-off tone in recent sessions has pushed flows toward safe-havens, creating mixed near-term demand for corporate credit
  • Direct exposure to corporate credit and interest-rate sensitivity — ETF performance tied to yield moves and credit spread direction
  • Liquidity and intraday tradability of the ETF provide investors a convenient route to corporate bond exposure relative to individual bonds
  • Limited issuer-specific disclosures or recent filings provided, increasing reliance on macro and sector drivers for near-term performance
  • Geopolitical headlines produced brief safe-haven rotations that could transiently tighten or loosen corporate spreads depending on risk sentiment

Risks

  • Rising benchmark interest rates that reduce bond prices and pressure ETF NAV
  • Widening corporate credit spreads from recession signals or increased default risk
  • Reduced liquidity in underlying corporate bond markets that can cause tracking deviation or larger intraday spreads
  • Concentrated sector or issuer weakness inside the underlying portfolio leading to idiosyncratic drawdowns
  • Limited forward visibility due to lack of recent filings or social/research signals; surprises could shift flows quickly

See today's live rating, score and targets

Members see the live hourly rating for IBD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.